and balstilimab (BOT+BAL) program entering 2026. The ses...[Back to Newsroom]## Wish your news had this kind of reach?[Sign Up][Learn About Business Wire] adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit [www.agenusbio.com] or @agenus_bio. Information that may be important to investors will be ...

Core Insights - Agenus Inc. announced new data from its botensilimab (BOT) immunotherapy program will be presented at the AACR-IO Conference, focusing on systemic and tumor inflammation biomarkers in immunologically cold tumors [1] Group 1: Presentation Details - The poster presentation titled "Systemic and tumor-microenvironment inflammation shape outcomes in patients with immunologically cold, treatment-refractory tumors treated with Fc-enhanced anti–CTLA-4 botensilimab" will evaluate the association of systemic inflammatory markers and tumor microenvironment immune activity with clinical outcomes [1] - The presentation will take place on February 19, 2026, from 12:15 PM to 3:15 PM PT at the JW Marriott, Platinum Ballroom [1] Group 2: About Botensilimab and Balstilimab - Botensilimab is designed to enhance both innate and adaptive anti-tumor immune responses, particularly in "cold" tumors that typically respond poorly to standard therapies [1] - Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in clinical trials, showing clinical responses across nine metastatic, late-line cancers [1] - Balstilimab is a fully human monoclonal antibody that blocks PD-1 from interacting with its ligands, having been evaluated in over 900 patients with a favorable tolerability profile [1] Group 3: Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994, aiming to expand patient populations benefiting from cancer immunotherapy [1] - The company has robust development capabilities, including commercial and clinical cGMP manufacturing facilities, research, and global clinical operations [1]

Core Insights - Agenus Inc. has appointed José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025 [1] - Dr. Iglesias will oversee global medical affairs for botensilimab (BOT) and balstilimab (BAL) as they progress through Phase 3 evaluation [1] - The combination of BOT and BAL will be made available in selected countries through early-access mechanisms, including France's Autorisation d'Accès Compassionnel [1]

Core Insights - Agenus Inc. will host a virtual Stakeholder Briefing on October 21, 2025, focusing on updates regarding its immunotherapy combination botensilimab (BOT) and balstilimab (BAL) [1][3] - The briefing will feature insights from leading experts on recent clinical progress and expanding international access for BOT/BAL, moderated by Garo Armen, PhD, the company's CEO [1][3] Company Overview - Agenus is a leader in immuno-oncology with a comprehensive pipeline of immunological agents, founded in 1994 [4] - The company aims to expand patient populations benefiting from cancer immunotherapy through combination approaches, utilizing a variety of therapeutic methods [4] Product Information - Botensilimab (BOT) is designed to enhance anti-tumor immune responses and is effective in treating "cold" tumors that typically respond poorly to standard therapies [5][6] - Approximately 1,200 patients have been treated with BOT/BAL in phase 1 and phase 2 clinical trials, showing clinical responses across nine metastatic, late-line cancers [7] - Balstilimab (BAL) is a fully human monoclonal antibody that blocks PD-1 interactions, demonstrating clinical activity in over 900 patients [8]